Home > Insider Trading > Filing (0001181431-11-057214)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1484478	Furiex Pharmaceuticals Inc.	FURX	Pharmaceutical Preparations (2834)	271197863

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1033409	N Fredric Eshelman	C/O Furiex Pharmaceuticals, Inc. 3900 Paramount Parkway, Suite 150 Morrisville NC 27560		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-11-18	23,625	$15.87	1,647,734	No	4	P	Direct
Common Stock	Acquisiton	2011-11-21	12,468	$15.48	1,660,202	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	41,666	Indirect	GRAT
Common Stock	938	Indirect	LLC
Common Stock	140	Indirect	Spouse

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Options (to buy)	$13.16		2021-10-03	98,813	98,813	Indirect
Common Stock	Stock Options (to buy)	$9.11		2020-06-17	197,627	197,627	Indirect

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2021-10-03	98,813	98,813	Indirect
2020-06-17	197,627	197,627	Indirect

Footnotes

This transaction was executed in multiple trades at prices ranging from $15.74 to $15.99. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
This transaction was executed in multiple trades at prices ranging from $15.25 to $15.50. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
The options were awarded on 10/3/2011 and vest over three years, with one-third of the options vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.
The options were awarded on 6/17/2010 and vest over three years, with one-third of the options vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's consulting relationship continues.